Madrigal Pharmaceuticals, Inc. (MDGL)
Develops medicines to treat fatty liver disease
$538.80-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+78.3%
The outlook
MDGL is trading near $539 with strong analyst backing—the consensus leans heavily "Strong Buy" across 15 analysts. The stock sits well above its longer-term moving averages and trades in the upper portion of its 52-week range, reflecting sustained upward momentum. Analysts' average price target sits roughly 26% above the current level.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +26% vs current price
Analyst price target
~12-month · 15 analysts$680.00average target+26.2% vs now
Now $538.80
Low $553.00High $964.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$12.42B
52-wk high
$615.00
52-wk low
$286.44
50-day avg
$517.38
200-day avg
$505.63
Trailing P/E
—